|Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non …|
T Mäkikallio, NR Holm, M Lindsay, MS Spence, A Erglis, IBA Menown, ...
The Lancet 388 (10061), 2743-2752, 2016
|Preeclampsia and future cardiovascular health: a systematic review and meta-analysis|
P Wu, R Haththotuwa, CS Kwok, A Babu, RA Kotronias, C Rushton, ...
Circulation: Cardiovascular Quality and Outcomes 10 (2), e003497, 2017
|Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy …|
P Vranckx, M Valgimigli, P Jüni, C Hamm, PG Steg, D Heg, GA van Es, ...
The Lancet 392 (10151), 940-949, 2018
|Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease …|
PS Douglas, G Pontone, MA Hlatky, MR Patel, BL Norgaard, RA Byrne, ...
European heart journal 36 (47), 3359-3367, 2015
|Atrial fibrillation after coronary artery bypass surgery: a model for preoperative risk stratification|
AG Zaman, RA Archbold, G Helft, EA Paul, NP Curzen, PG Mills
Circulation 101 (12), 1403-1408, 2000
|The role of plaque rupture and thrombosis in coronary artery disease|
AG Zaman, G Helft, SG Worthley, JJ Badimon
Atherosclerosis 149 (2), 251-266, 2000
|Thyroid hormones and cardiovascular function and diseases|
S Razvi, A Jabbar, A Pingitore, S Danzi, B Biondi, I Klein, R Peeters, ...
Journal of the American College of Cardiology 71 (16), 1781-1796, 2018
|Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non …|
NR Holm, T Mäkikallio, MM Lindsay, MS Spence, A Erglis, IBA Menown, ...
The Lancet 395 (10219), 191-199, 2020
|Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure|
MT Kearney, KAA Fox, AJ Lee, RJ Prescott, AM Shah, PD Batin, W Baig, ...
Journal of the American College of Cardiology 40 (10), 1801-1808, 2002
|Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study|
J Escaned, C Collet, N Ryan, G Luigi De Maria, S Walsh, M Sabate, ...
European heart journal 38 (42), 3124-3134, 2017
|Radial artery anomaly and its influence on transradial coronary procedural outcome|
TS Lo, J Nolan, E Fountzopoulos, M Behan, R Butler, SL Hetherington, ...
Heart 95 (5), 410-415, 2009
|Does routine pressure wire assessment influence management strategy at coronary angiography for diagnosis of chest pain? The RIPCORD study|
N Curzen, O Rana, Z Nicholas, P Golledge, A Zaman, K Oldroyd, ...
Circulation: Cardiovascular Interventions 7 (2), 248-255, 2014
|Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control|
JI Osende, JJ Badimon, V Fuster, P Herson, P Rabito, R Vidhun, A Zaman, ...
Journal of the American College of Cardiology 38 (5), 1307-1312, 2001
|Polymer-based or polymer-free stents in patients at high bleeding risk|
S Windecker, A Latib, E Kedhi, AJ Kirtane, DE Kandzari, R Mehran, ...
New England Journal of Medicine 382 (13), 1208-1218, 2020
|Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY …|
KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ...
The lancet Diabetes & endocrinology 7 (8), 618-628, 2019
|Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo …|
DL Bhatt, PG Steg, SR Mehta, LA Leiter, T Simon, K Fox, C Held, ...
The Lancet 394 (10204), 1169-1180, 2019
|Serial in vivo MRI documents arterial remodeling in experimental atherosclerosis|
SG Worthley, G Helft, V Fuster, AG Zaman, ZA Fayad, JT Fallon, ...
Circulation 101 (6), 586-589, 2000
|Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras|
RM Cubbon, CP Gale, LC Kearney, CB Schechter, WP Brooksby, J Nolan, ...
Circulation: Heart Failure 4 (4), 396-403, 2011
|Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents|
A Natarajan, AG Zaman, SM Marshall
Diabetes and Vascular Disease Research 5 (2), 138-144, 2008
|Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation|
AG Zaman, MT Kearney, C Schecter, SG Worthley, J Nolan
American Heart Journal 147 (5), 823-827, 2004